Evaluation Of An In-house Specific Immunoglobulin G (igg) Avidity Elisa For Distinguishing Recent Primary From Long-term Human Cytomegalovirus (hcmv) Infection.

This article describes the standardization and evaluation of an in-house specific IgG avidity ELISA for distinguishing recent primary from long-term human cytomegalovirus (HCMV) infection. The test was standardized with the commercial kit ETI-CYTOK G Plus (Sorin Biomedica, Italy) using 8 M urea in phosphate-buffered saline to dissociate low-avidity antibodies after the antigen-antibody interaction. The performance of the in-house assay was compared to that of the commercial automated VIDAS CMV IgG avidity test (bioM rieux, France). Forty-nine sera, 24 from patients with a recent primary HCMV infection and 25 from patients with a long-term HCMV infection and a sustained persistence of specific IgM antibodies, were tested. Similar results were obtained with the two avidity methods. All 24 sera from patients with recently acquired infection had avidity indices compatible with acute HCMV infection by the VIDAS method, whereas with the in-house method, one serum sample had an equivocal result. In the 25 sera from patients with long-term infection, identical results were obtained with the two methods, with only one serum sample having an incompatible value. These findings suggest that our in-house avidity test could be a potentially useful tool for the immunodiagnosis of HCMV infection.45323-

Avaliação de um teste de avidez imunoenzimático para o citomegalovírus humano (ELISA-HCMV) para distinguir a infecção primária recente da infecção de longa duração

This article describes the standardization and evaluation of an in-house specific IgG avidity ELISA for distinguishing recent primary from long-term human cytomegalovirus (HCMV) infection. The test was standardized with the commercial kit ETI-CYTOK G Plus (Sorin Biomedica, Italy) using 8 M urea in phosphate-buffered saline to dissociate low-avidity antibodies after the antigen-antibody interaction. The performance of the in-house assay was compared to that of the commercial automated VIDAS CMV IgG avidity test (bioMérieux, France). Forty-nine sera, 24 from patients with a recent primary HCMV infection and 25 from patients with a long-term HCMV infection and a sustained persistence of specific IgM antibodies, were tested. Similar results were obtained with the two avidity methods. All 24 sera from patients with recently acquired infection had avidity indices compatible with acute HCMV infection by the VIDAS method, whereas with the in-house method, one serum sample had an equivocal result. In the 25 sera from patients with long-term infection, identical results were obtained with the two methods, with only one serum sample having an incompatible value. These findings suggest that our in-house avidity test could be a potentially useful tool for the immunodiagnosis of HCMV infection.Este artigo descreve a padronização e avaliação de um teste de avidez imunoenzimático para o citomegalovírus humano (ELISA-HCMV) para distinguir a infecção primária recente da infecção de longa duração. O teste foi padronizado com o kit comercial ETI-CYTOK G Plus (Sorin Biomedica, Itália), utilizando uréia 8 M para a dissociação dos anticorpos de baixa avidez. A performance do teste ELISA-HCMV foi comparada com a do teste de avidez comercial automatizado VIDAS CMV IgG (bioMérieux, França), utilizando 24 soros de pacientes com infecção primária recente e 25 soros de pacientes com infecção de longa duração apresentando persistência de anticorpos específicos IgM. Resultados similares foram obtidos com os dois métodos de avidez. Todos os 24 soros de pacientes com infecção recentemente adquirida apresentaram índices de avidez compatíveis com infecção aguda pelo HCMV utilizando o teste VIDAS CMV IgG, enquanto que um dos soros apresentou resultado duvidoso no teste ELISA-HCMV. Os 25 soros de pacientes com infecção de longa duração apresentaram resultados idênticos com os dois métodos, com apenas um dos soros apresentando um valor não compatível. Estes resultados sugerem que o teste de avidez descrito pode ser potencialmente útil para o imunodiagnóstico da infecção pelo HCMV

Avaliação de um teste de avidez imunoenzimático para o citomegalovírus humano (ELISA-HCMV) para distinguir a infecção primária recente da infecção de longa duração

This article describes the standardization and evaluation of an in-house specific IgG avidity ELISA for distinguishing recent primary from long-term human cytomegalovirus (HCMV) infection. The test was standardized with the commercial kit ETI-CYTOK G Plus (Sorin Biomedica, Italy) using 8 M urea in phosphate-buffered saline to dissociate low-avidity antibodies after the antigen-antibody interaction. The performance of the in-house assay was compared to that of the commercial automated VIDAS CMV IgG avidity test (bioMérieux, France). Forty-nine sera, 24 from patients with a recent primary HCMV infection and 25 from patients with a long-term HCMV infection and a sustained persistence of specific IgM antibodies, were tested. Similar results were obtained with the two avidity methods. All 24 sera from patients with recently acquired infection had avidity indices compatible with acute HCMV infection by the VIDAS method, whereas with the in-house method, one serum sample had an equivocal result. In the 25 sera from patients with long-term infection, identical results were obtained with the two methods, with only one serum sample having an incompatible value. These findings suggest that our in-house avidity test could be a potentially useful tool for the immunodiagnosis of HCMV infection.Este artigo descreve a padronização e avaliação de um teste de avidez imunoenzimático para o citomegalovírus humano (ELISA-HCMV) para distinguir a infecção primária recente da infecção de longa duração. O teste foi padronizado com o kit comercial ETI-CYTOK G Plus (Sorin Biomedica, Itália), utilizando uréia 8 M para a dissociação dos anticorpos de baixa avidez. A performance do teste ELISA-HCMV foi comparada com a do teste de avidez comercial automatizado VIDAS CMV IgG (bioMérieux, França), utilizando 24 soros de pacientes com infecção primária recente e 25 soros de pacientes com infecção de longa duração apresentando persistência de anticorpos específicos IgM. Resultados similares foram obtidos com os dois métodos de avidez. Todos os 24 soros de pacientes com infecção recentemente adquirida apresentaram índices de avidez compatíveis com infecção aguda pelo HCMV utilizando o teste VIDAS CMV IgG, enquanto que um dos soros apresentou resultado duvidoso no teste ELISA-HCMV. Os 25 soros de pacientes com infecção de longa duração apresentaram resultados idênticos com os dois métodos, com apenas um dos soros apresentando um valor não compatível. Estes resultados sugerem que o teste de avidez descrito pode ser potencialmente útil para o imunodiagnóstico da infecção pelo HCMV.323326Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES

Surveillance Of Cytomegalovirus Infection In Haematopoietic Stem Cell Transplantation Patients.

The aim of this study was to describe our experience in the control of active CMV infection following HSCT using two strategies of CMV infection treatment: ganciclovir universal prophylaxis at low doses and pre-emptive therapy with ganciclovir. The surveillance was based on the monitoring of antigenaemia (AGM) and on a nested polymerase chain reaction (N-PCR) for the detection of CMV in both strategies. Forty-five recipients with malignant diseases and with a risk for CMV disease received universal prophylaxis (Group A). The non-treated group consisted of 24 patients, most of them with non-malignant diseases who did not receive universal prophylaxis (Group B). In Group A, the incidence of positive AGM was 51%, with a positive PCR of 68.9%. In Group B, the AGM positivity was 66.7% and that of N-PCR was 66.7%. CMV disease occurred in 6/55 patients (10.9%), with 2/36 (5.5%) from Group A and 4/19 (21%) from Group B. Two of these six patients (33.3%) died of CMV disease. Our result suggests that AGM and N-PCR can be used as markers for assessing the monitoring and the introduction pre-emptive therapy. This approach could prove to be more cost-effective than ganciclovir universal prophylaxis for treating CMV infection.50130-